Kenvue, Inc. (KVUE)

Kenvue's stock price has been impacted by several events in the past six months. A controversy arose in September 2025 when former President Donald Trump linked acetaminophen to autism during pregnancy, leading to a stock drop and increased regulatory risks. Concerns were raised about potential conflicts of interest when three U.S. lawmakers sold shares in Kenvue shortly before the Tylenol controversy. In June 2025, shares tumbled due to challenges in seasonal demand for products like allergy medicine and sunscreen. The CEO also noted the impact of retailer de-stocking and broader consumer pressures. The company adjusted its FY25 EPS guidance, forecasting flat growth from FY24. Kenvue disclosed an increase in its quarterly dividend to $0.2075. Between October 2, 2024, and October 1, 2025, Kenvue's share price declined by 29.96%, reaching an all-time low of $15.47 on October 1, 2025.

Kenvue's products experience demand seasonality, particularly in its Self Care segment. Seasonal demand for products like allergy medicine and sunscreen was impacted by a longer winter, which delayed the onset of spring into the second quarter, affecting Q2 results.

Kenvue, Inc. is a global consumer health company spun off from Johnson & Johnson in 2023, operating in the Consumer Staples sector. Its business focuses on health and wellness solutions through well-known brands across three segments: Self Care, which includes OTC medications like Tylenol and Zyrtec; Skin Health and Beauty, featuring brands like Neutrogena and Aveeno; and Essential Health, which includes brands like Listerine and Johnson's.

Kenvue has a significant global presence, operating in over 165 countries. Approximately half of its net sales are generated outside North America, with sales distributed across North America, Europe, Asia-Pacific, and Latin America.

Kenvue's brand reputation has been significantly affected by the controversy surrounding Tylenol. Assertions linking acetaminophen use during pregnancy to autism sparked scrutiny and a potential FDA warning. Kenvue has defended the safety of acetaminophen, emphasizing the lack of credible evidence linking it to autism. This event has brought regulatory and litigation risks to the forefront, impacting consumer confidence and sales.

Kenvue's ownership is predominantly institutional, with institutional shareholders holding approximately 99.46% of the company's stock. Major institutional owners include Vanguard Group Inc., Price T Rowe Associates Inc /Md/, BlackRock, Inc., State Street Corp, Fmr Llc, and Massachusetts Financial Services Co /Ma/. Johnson & Johnson is the largest individual shareholder, owning 9.50% of the company. Insiders hold about 10.63% of Kenvue's stock.